Top 10 galencentre.org Competitors

cspi.org

CSPI supports policies aimed at keeping our food supply free of dangerous pathogens like Salmonella, E. coli, and Listeria. We led the fight for national legislation that promises safer produce, and whole and processed foods that are regulated by FDA. Now CSPI is working to bring the same modernizing concepts to the USDA’s oversight of meat and poultry safety.

guttmacher.org

When state legislatures roared back into session in January 2018, sexual and reproductive health and rights were once again front-burner issues in capitols across the country. But this year’s sessions are notable for a real focus on positive legislation. By the end of the first quarter, eight states and the District of Columbia had adopted 25 measures to expand access to abortion, contraception, other reproductive health services and comprehensive sex education or to protect reproductive rights.

who.int

The United Nations agency working to promote health, keep the world safe and serve the vulnerable.

nuffieldtrust.org.uk

Facts on staffing and staff shortages in England.

healthsystemtracker.org

This interactive tool provides up-to-date information on U.S. health spending by federal and local governments, private companies, and individuals. It was developed by KFF using data from the National Health Expenditure Accounts of the Centers for Medicare & Medicaid Services and will be updated annually with each data release. For help using this tool, check […]

hhmi.org

Loren Frank’s HHMI lab at UCSF has pioneered an ambitious framework for sharing vast neuroscience datasets and complicated analysis methods, a step towards tipping the culture of science towards more effective and fruitful collaboration.

bmcnephrol.biomedcentral.com

Non-melanoma skin cancer is a prevalent complication in renal transplant recipients due to long-term immunosuppressive therapy. Calcineurin inhibitors, such as tacrolimus and cyclosporine, are effective in preventing graft rejection; however, they significantly increase the risk of non-melanoma skin cancer through broad immunosuppressive and pro-oncogenic mechanisms. Belatacept, a selective co-stimulation blocker targeting the CD80/CD86-CD28 axis, has emerged as a mechanistically distinct alternative with potential benefits for oncologic and renal outcomes. The primary objective of this review is to examine the impact of belatacept-based immunosuppression on the incidence and progression of non-melanoma skin cancer in renal transplant recipients, compared to conventional Calcineurin inhibitors. Secondary objectives include evaluating the immunologic mechanisms underlying its distinct cancer risk profile, exploring combinatory regimens (particularly with mammalian target of rapamycin inhibitors), assessing metabolic and nephrotoxic implications, and addressing ethical and clinical considerations in switching stable patients from Calcineurin inhibitors to belatacept. Although retrospective studies suggest a lower incidence of non-melanoma skin cancer with belatacept, robust prospective data remain limited, and its use is associated with increased early rejection and post-transplant lymphoproliferative disorder risk, particularly in Epstein-Barr virus seronegative patients. Emerging molecular biomarkers and transcriptomic insights may facilitate the development of personalized immunosuppression strategies. Further randomized controlled trials and longitudinal studies are essential to clarify belatacept’s oncologic safety and optimize immunosuppressive protocols in high-risk transplant populations.

fpf.org

Who supports FPF's work? FPF brings together a range of voices from industry, academia, and civil society to lead collaboration and ensure the diversity of ideas necessary to advance principled data practices in support of emerging technologies. FPF values the guidance and contributions of a wide range of members and foundation…